123 related articles for article (PubMed ID: 14501379)
41. Novel heptapeptide somatostatin analog displays anti-tumor activity independent of effects on growth hormone secretion.
Murphy WA; Taylor JE; Moreau JP; Coy DH
Pept Res; 1989; 2(1):128-32. PubMed ID: 2577697
[TBL] [Abstract][Full Text] [Related]
42. The mu-opioid receptor antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) [but not D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP)] produces a nonopioid receptor-mediated increase in K+ conductance of rat locus ceruleus neurons.
Chieng B; Connor M; Christie MJ
Mol Pharmacol; 1996 Sep; 50(3):650-5. PubMed ID: 8794906
[TBL] [Abstract][Full Text] [Related]
43. Agonist properties of putative small-molecule somatostatin sst2 receptor-selective antagonists.
Nunn C; Langenegger D; Hurth K; Schmidt K; Fehlmann D; Hoyer D
Eur J Pharmacol; 2003 Apr; 465(3):211-8. PubMed ID: 12681432
[TBL] [Abstract][Full Text] [Related]
44. Antiproliferative activity induced by the somatostatin analogue, TT-232, in human pancreatic cancer cells.
Lee JU; Hosotani R; Wada M; Doi R; Koshiba T; Fujimoto K; Miyamoto Y; Tsuji S; Nakajima S; Hirohashi M; Uehara T; Arano Y; Fujii N; Imamura M
Eur J Cancer; 2002 Jul; 38(11):1526-34. PubMed ID: 12110500
[TBL] [Abstract][Full Text] [Related]
45. Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model.
Yano T; Pinski J; Szepeshazi K; Milovanovic SR; Groot K; Schally AV
Prostate; 1992; 20(4):297-310. PubMed ID: 1351672
[TBL] [Abstract][Full Text] [Related]
46. Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors.
Lee MT; Liebow C; Kamer AR; Schally AV
Proc Natl Acad Sci U S A; 1991 Mar; 88(5):1656-60. PubMed ID: 1672042
[TBL] [Abstract][Full Text] [Related]
47. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination.
Szepeshazi K; Milovanovic S; Lapis K; Groot K; Schally AV
Breast Cancer Res Treat; 1992; 21(3):181-92. PubMed ID: 1355375
[TBL] [Abstract][Full Text] [Related]
48. Microinjection of exogenous somatostatin in the dorsal vagal complex inhibits pancreatic secretion via somatostatin receptor-2 in rats.
Liao Z; Li ZS; Lu Y; Wang WZ
Am J Physiol Gastrointest Liver Physiol; 2007 Mar; 292(3):G746-52. PubMed ID: 17138968
[TBL] [Abstract][Full Text] [Related]
49. The somatostatin analogue peptide TT-232 induces apoptosis and chromosome breakage in cultured human lymphocytes.
Tompa A; Jakab MG; Major J; Idei M; Bocsi J; Mihalik R; Szende B; Kéri G
Mutat Res; 2000 Feb; 465(1-2):61-8. PubMed ID: 10708970
[TBL] [Abstract][Full Text] [Related]
50. Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology.
Msaouel P; Galanis E; Koutsilieris M
Expert Opin Investig Drugs; 2009 Sep; 18(9):1297-316. PubMed ID: 19678799
[TBL] [Abstract][Full Text] [Related]
51. Effect of somatostatin analogs on gastric acid secretion in dogs and rats.
Schally AV; Colaluca J; Paulson D; Carter WH; Neitzschman HR; Lafaye H; Cai RZ
Int J Pept Protein Res; 1990 Sep; 36(3):267-74. PubMed ID: 1980670
[TBL] [Abstract][Full Text] [Related]
52. Treatment of N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and somatostatin analogue RC-160 microcapsules.
Zalatnai A; Schally AV
Cancer Res; 1989 Apr; 49(7):1810-5. PubMed ID: 2564312
[TBL] [Abstract][Full Text] [Related]
53. Structure-activity relationship studies optimizing the antiproliferative activity of novel cyclic somatostatin analogues containing a restrained cyclic beta-amino acid.
Sukopp M; Schwab R; Marinelli L; Biron E; Heller M; Várkondi E; Pap A; Novellino E; Kéri G; Kessler H
J Med Chem; 2005 Apr; 48(8):2916-26. PubMed ID: 15828830
[TBL] [Abstract][Full Text] [Related]
54. Synthesis, Cytotoxicity and Antioxidant Activity of New Analogs of RC-121 Synthetic Derivatives of Somatostatin.
Naydenova E; Wesselinova D; Staykova S; Goshev I; Vezenkov L
Anticancer Agents Med Chem; 2018; 18(10):1417-1424. PubMed ID: 29667555
[TBL] [Abstract][Full Text] [Related]
55. Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from rat pituitary cells.
Moore SB; van der Hoek J; de Capua A; van Koetsveld PM; Hofland LJ; Lamberts SW; Goodman M
J Med Chem; 2005 Oct; 48(21):6643-52. PubMed ID: 16220980
[TBL] [Abstract][Full Text] [Related]
56. A somatostatin analogue inhibits MAP kinase activation and cell proliferation in human neuroblastoma and in human small cell lung carcinoma cell lines.
Cattaneo MG; Amoroso D; Gussoni G; Sanguini AM; Vicentini LM
FEBS Lett; 1996 Nov; 397(2-3):164-8. PubMed ID: 8955339
[TBL] [Abstract][Full Text] [Related]
57. Somatostatin analogs and radiopeptides in cancer therapy.
Froidevaux S; Eberle AN
Biopolymers; 2002; 66(3):161-83. PubMed ID: 12385036
[TBL] [Abstract][Full Text] [Related]
58. Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.
Radulovic S; Comaru-Schally AM; Milovanovic S; Schally AV
Pancreas; 1993 Jan; 8(1):88-97. PubMed ID: 8093555
[TBL] [Abstract][Full Text] [Related]
59. Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study.
Dimopoulos MA; Kiamouris C; Gika D; Deliveliotis C; Giannopoulos A; Zervas A; Alamanis C; Constantinidis C; Koutsilieris M
Urology; 2004 Jan; 63(1):120-5. PubMed ID: 14751362
[TBL] [Abstract][Full Text] [Related]
60. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.
Florio T; Thellung S; Corsaro A; Bocca L; Arena S; Pattarozzi A; Villa V; Massa A; Diana F; Schettini D; Barbieri F; Ravetti JL; Spaziante R; Giusti M; Schettini G
Clin Endocrinol (Oxf); 2003 Jul; 59(1):115-28. PubMed ID: 12807513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
